Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.75 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | CCNK | O75909 | 1/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CCND3 | P30281 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25869936 | 0.94 | EGFR (0.76) | ALKEGFRZAP70INSRIGF1R | |
| SCHEMBL25872145 | 0.94 | ALK (0.66) | ALKEGFRZAP70 | |
| SCHEMBL25871546 | 0.92 | ALK (0.64) | ALKEGFRZAP70INSRIGF1R | |
| SCHEMBL25872847 | 0.92 | ALK (0.63) | ALKEGFRZAP70INSRIGF1R | |
| SCHEMBL29059678 | 0.90 | ALK (0.74) | ALKEGFRZAP70INSRIGF1R | |
| SCHEMBL30497488 | 0.90 | ALK (0.74) | ALKEGFRZAP70 | |
| SCHEMBL26495301 | 0.90 | ALK (0.74) | ALKEGFRZAP70 | |
| SCHEMBL21847010 | 0.87 | ALK (0.81) | ALKEGFRINSRIGF1RCCNK | |
| SCHEMBL25870489 | 0.86 | ALK (0.56) | ALKEGFRZAP70INSRIGF1R | |
| SCHEMBL16752969 | 0.86 | ALK (1.00) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |